News Digest / Ticker: UPB

Ticker: UPB

08:11am, Wednesday, Aug 06, 2025

Upstream Bio Reports Q2 2025 Losses Amid Rising R&D Costs and Promising Clinical Developments

Upstream Bio, Inc. (NASDAQ: UPB) - Q2 2025 Analysis Upstream Bio, Inc. has reported its Q2 2025 financials, revealing a notable expansion in operating expenses amidst continuing development efforts for its clinical-stage product candidate, verekitug. Key Financial Metrics Net Loss: $39.97 millio...

08:05am, Tuesday, May 06, 2025

Upstream Bio Reports $27.3M Q1 Loss While Advancing Verekitug for Respiratory Disorders